Pfizer Inc. (PFE)
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.
I Sold Pfizer at a 13% Loss – Here's Why I'm Choosing Stability Over Risk
A Reddit poster took a big loss on Pfizer. They needed to dump some shares because they occupied a huge chunk of their portfolio.
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Oxford BioDynamics shares jump 66% after Pfizer validates blood-based cancer biomarker technology
Oxford BioDynamics PLC (AIM:OBD) shares jumped 66% after Pfizer published data confirming the effectiveness of the company's EpiSwitch blood-based biomarkers in monitoring tumour status and treatment response in bladder cancer patients. The findings, from the JAVELIN Bladder 100 Trial involving 496 patients, were featured in the journal Cancers.
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note
Pfizer (PFE) closed at $25.62 in the latest trading session, marking a +1.51% move from the prior day.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)
Shares of Pfizer ( NYSE: PFE ) surged 8.24% over the past month, reducing the stock's year-to-date loss to 5.02%.
Pfizer: Options Activity Speaks Bullish
The call activity above the current Pfizer Inc. share price, increasing call premiums, and the lack of defensive put buying point to options traders expecting Pfizer to move higher from current price. Cost-saving initiatives, strong free cash flow, and a large R&D budget, support future growth and innovation, with recent pipeline successes as catalysts. Despite macro risks and ROIC below historical averages, PFE stock's 52% upside to fair value and compelling yield make it a rare value opportunity.
Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
In the latest trading session, Pfizer (PFE) closed at $25.32, marking a +1.12% move from the previous day.
